A review of the potential role of methylnaltrexone in opioid bowel dysfunction

American Journal of Surgery

Volumn 182, Issue 5 SUPPL., 2001, Pages S19-S26

  Foss, Joseph F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; NALMEFENE; NALOXONE; NALTREXONE; OPIATE; OPIATE ANTAGONIST;

ADVANCED CANCER; ANALGESIA; BLOOD BRAIN BARRIER; CANCER; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG WITHDRAWAL; ENTEROPATHY; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; HUMAN; INTESTINE MOTILITY; LONG TERM CARE; PRIORITY JOURNAL; REVIEW; WITHDRAWAL SYNDROME;

EID: 0035690146     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(01)00783-8     Document Type: Article

References (33)

1. Side effects of morphine administration in cancer patients
2. Prevalence and pattern of symptoms in patients with cancer pain: A prospective evaluation of 1635 cancer patients referred to a pain clinic
3. A long-term survey of morphine in cancer pain patients
4. Management of opioid-induced constipation
5. Prevention of opioid side effects
6. Incidence, prevalence, and management of opioid bowel dysfunction
7. Gut motility and transit changes in patients receiving long-term methadone maintenance
8. Morphine, constipation, and performance status in advanced cancer patients
9. Unrecognized constipation in patients with advanced cancer: A recipe for therapeutic disaster
10. Utility assessments of opioid treatment for patients with chronic non-cancer pain
11. Assessment of nalmefene glucuronide as a selective gut opioid antagonist
12. Antagonism of gut but not central effects of morphine with quaternary narcotic antagonists
13. Peptide opioid antagonist separates peripheral and central opioid antitransit effects
14. Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites
15. The central and peripheral influence of opioids on gastrointestinal propulsion
16. Naloxone
17. Treatment of opioid-induced constipation with oral naloxone: A pilot study
18. Oral naloxone reverses opioid-associated constipation
19. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer
20. The use of quaternary narcotic antagonists in opiate research
21. Quaternary narcotic antagonists' relative ability to prevent antinociception and gastrointestinal transit inhibition in morphine-treated rats as an index of peripheral selectivity
22. Safety and tolerance of methylnaltrexone in healthy humans: A randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study
23. Reversal of morphine-induced catalepsy in the rat by narcotic antagonists and their quaternary derivatives
24. Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists
25. Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans
26. Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats
27. Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs
28. Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea pig ileum and human intestine
29. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: A double-blind randomized placebo-controlled trial
30. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time
31. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time
32. Methylnaltrexone for reversal of constipation due to chronic methadone use
33. Oral methylnaltrexone for opioid-induced constipation